Stapokibart reduces blood eosinophil counts in patients with moderate-to-severe atopic dermatitis
a post-hoc analysis from phase II and phase III clinical trials.
Zhao Y, Zhang F, Yang B, Zhang L, Wu L, Ding Y, Wang J, Li Y, Diao Q, Li J, Sun Q, Zhu X, Man X, Wang L, Feng Y, Cai T, Zeng H, Li L, Lu J, Ren H, Li F, Lu Q, Tao X, Xiao R, Zhang C, Xia X, Cheng H, Ji C, Zhao W, Qiu Y, Chu W, Yan H, Chen B, Zhang J
Journal of Dermatological TreatmentIn the feed 15 Jul 2026, published online 15 Jul 2026, issue 2026 Dec, added to PubMed 15 Jul 2026
Topics: Atopic dermatitis & eczema
Abstract
BACKGROUNDEosinophils are involved in the pathogenesis of atopic dermatitis (AD).
OBJECTIVEThis post-hoc analysis evaluated the effect of stapokibart on blood eosinophil counts in moderate-to-severe AD patients.
METHODSThe phase II AD002 trial (n = 120) randomly assigned patients to stapokibart 300 mg every 2 weeks (Q2W), 150 mg Q2W, or placebo for 16 weeks. The phase III AD005 trial (n = 500) randomly assigned patients to stapokibart 300 mg Q2W or placebo for 16 weeks, followed by open-label stapokibart 300 mg Q2W for 36 weeks. Efficacy and safety were analyzed in subgroups stratified by baseline blood eosinophil counts (≥500 or <500 cells/µL).
RESULTSStapokibart treatment resulted in sustained reductions in blood eosinophil counts versus placebo (baseline vs. Week 16: high-dose 420 vs. 235 cells/μL, low-dose 530 vs. 315 cells/μL in AD002; 370 vs. 210 cells/μL in AD005). Furthermore, stapokibart demonstrated superior efficacy over placebo in achieving higher Eczema Area and Severity Index (EASI)-75 response rates at Week 16 in both eosinophil subgroups. The incidence of adverse events was similar across eosinophil subgroups, with most events being mild or moderate.
CONCLUSIONStapokibart reduced blood eosinophil counts in AD patients and demonstrated favorable efficacy and safety regardless of baseline blood eosinophil counts.
Abstract from PubMed
PMID 42454692 · DOI 10.1080/09546634.2026.2670906